Quick Answer
Acurx Pharmaceuticals, Inc. reported Stockholders Equity of $5.27 million for the year ending 2025.
- Acurx Pharmaceuticals, Inc. showed an increase of +756.5% in Stockholders Equity from 2024 to 2025.
- This data is from Acurx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $2.47 million | Q2 2021: $15.52 million | Q3 2021: $14.28 million | Q1 2022: $10.69 million | Q2 2022: $8.79 million | Q3 2022: $9.76 million | Q1 2023: $5.31 million | Q2 2023: $6.22 million | Q3 2023: $3.93 million | Q1 2024: $6.00 million | Q2 2024: $3.43 million | Q3 2024: $2.66 million | Q1 2025: $2.31 million | Q2 2025: $3.57 million | Q3 2025: $3.64 million.
- Over the full 6 years of available data (2020 to 2025), Acurx Pharmaceuticals, Inc.'s Stockholders Equity has grown by 95.0%.
- Historical annual values: Fiscal year 2025: $5.27 million | Fiscal year 2024: $615.1 thousand | Fiscal year 2023: $4.67 million | Fiscal year 2022: $7.32 million | Fiscal year 2021: $12.41 million | Fiscal year 2020: $2.70 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: